New treatments using bispecific antibodies for childhood brain tumors
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma
This study is looking at a new treatment that helps the body's immune cells better fight solid tumors and brain tumors in kids, like neuroblastoma and diffuse midline glioma, by making it easier for these immune cells to reach and attack the cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10892246 on NIH RePORTER |
What this research studies
This research focuses on developing bispecific T cell engagers (BTEs) to improve immunotherapy for pediatric patients with solid tumors and brain tumors, such as neuroblastoma and diffuse midline glioma. The approach aims to enhance T cell infiltration into tumors and overcome barriers like the blood-brain barrier, which often prevents effective treatment. By connecting cancer cells to the body's own T cells, this therapy seeks to stimulate a stronger immune response against the tumors. The research includes innovative strategies to promote T cell movement into tumors and to understand how these therapies can be effective even when traditional methods fail.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients under 11 years old diagnosed with solid tumors or brain tumors.
Not a fit: Patients with tumors that are not solid or brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with difficult-to-treat brain tumors, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise with bispecific antibodies in treating other cancers, indicating potential for success in this novel application.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Olson, James M — Seattle Children's Hospital
- Study coordinator: Olson, James M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.